CompletedNot Applicable

Triple Procedure for Dense Cataractus Neovascular Glaucoma Patients

Egypt12 participantsStarted 2016-07-01

Plain-language summary

Background: One of the most difficult refractory glaucomas in treatment is the neovascular type and its association with dense cataract add to this difficulty. This study aimed to provide results of triple surgical treatment of such conditions. Methods: A total of 12 eyes of 12 patients with dense cataractus NVG patients were included in this study. The patients mean age was 57.25 ± 5.9 years. The mean pre-operative intraocular pressure (IOP) was 47.25 ± 4.04 mmHg with maximum antiglaucoma therapy. The mean best corrected distant visual acuities (BCDVA) in log MAR was 2.13 ± 0.38. All the patients received intra-vitreal injection of 1.25 mg (0.05 ml) bevacizumab followed by phacoemulsification, pars plana vitrectomy (PPV) including pan-retinal photocoagulation (PRP), and assisted trabeculectomy with Mitomycin c (MMC). Mean IOP and BCDVA changes were the main outcome results of this study.

Who can participate

Age range47 Years – 66 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The study included patients with uncontrolled angle closure dense cataractus NVG with maximum tolerated anti-glaucoma medications. Exclusion Criteria: * Excluded from this study eyes that had previous anti-glaucoma procedures, silicone oil filled eyes, previous buckle surgery or Conjunctival scaring from any cause, eyes with clear crystalline lens or faint cataract, eyes with corneal opacity, and eyes with visual acuity less than hand motion with good perception of light.

What they're measuring

BCDVA

Timeframe: 2 years

IOP

Timeframe: 2 years

Trial details

NCT IDNCT04143620

SponsorMinia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-31